Based on Clarity's multi-model valuation engine, Axsome Therapeutics, Inc. (AXSM) has an estimated fair value of $56.72 per share, compared to its current market price of $162.59. The stock is currently trading 65.1% above Clarity's fair value estimate, resulting in a verdict of SIGNIFICANTLY OVERVALUED.

This valuation blends 2 independent models — including EV/Revenue, Discounted Cash Flow (DCF). The primary weight is given to the EV/Revenue model, with Bayesian triangulation used to reconcile the estimates into a single blended fair value. The 2 models show moderate agreement with a 26% spread between the highest and lowest estimates.

Monte Carlo simulation across 5,000 scenarios estimates a 0.4% probability that the stock is trading below its intrinsic value, with a median simulated value of $51.82.

Clarity's 1-year price target is $79.18, reflecting expected earnings growth and margin trajectory.

Axsome Therapeutics, Inc. is classified under the Pharma / Biotech sector, and this valuation is based on 10-K · Filed 2026-02-23 filings sourced directly from SEC EDGAR. All models use trailing twelve month (TTM) financials where available, with sector-appropriate growth and discount rate assumptions.